Topic Pfizer

Companies Pfizer

News Pfizer

• Karo Bio Enters Collaboration with Pfizer to Discover and Develop Innovative Drugs for Autoimmune Diseases

  Karo Bio AB has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.Under the agreement, Pfizer will provide full funding for the research costs and have the exclusive right to mar more

• Sanofi Tops Pfizer As Number One For Global Pharma Sales

  EvaluatePharma Ltd revealed that Sanofi is expected to take the top spot amongst the world’s pharmaceuticals manufacturers in 2012 and hold it through 2016. The French drug maker has raced up the rankings over the last decade largely through M&A activity, with the $20bn purchase this year of US biot more

• Ablynx regains rights from Pfizer to nanobodies targeting TNF-alpha

  Ablynx announced that it has regained worldwide rights from Pfizer Inc. to develop and commercialise Nanobodies targeting TNF-alpha. These rights include the product ATN-103, for which positive proof-of-concept data from a Phase II trial in rheumatoid arthritis (RA) were announced in May of this yea more

White papers Pfizer

• Orphan Drugs – An Alternative to the declining Blockbuster Model?
  

  Up until the new millennium, the pharmaceutical industry grew stronger by 11%. However, the blockbuster model is increasingly at risk and the declining growth rates in the industry require a search for new strategies. In this context, orphan drugs are becoming increasingly important more

Publications Pfizer

• Reproductive Toxicity Assessment of Sunitinib, A Multitargeted Receptor Tyrosine Kinase Inhibitor, in Male and Female Rats

  BACKGROUND Sunitinib (SUTENT, Pfizer Inc., New York, NY) is a multitargeted inhibitor of selected receptor tyrosine kinases, which produces an antiproliferative and antiangiogenic effect by blocking pathways fundamental to tumor growth and survival. We investigated the effects of sunitinib on ma more

• Ligand Binding Assays in the 21st Century Laboratory—A Call for Change

  Ligand Binding Assays in the 21st Century Laboratory—A Call for Change Content Type Journal Article Category Editorial Pages 1-3 DOI 10.1208/s12248-012-9351-8 Authors Chad A. Ray, Pharmacokinetics Dynamics and Metabolism, Pfizer Worldwide Research & Development, La Jolla, California 921 more

• Oxytocin and Vasopressin Agonists and Antagonists as Research Tools and Potential Therapeutics

  Abstract We recently reviewed the status of peptide and non‐peptide agonists and antagonists for the V1a, V1b and V2 receptors for arginine vasopressin (AVP) and the oxytocin receptor for oxytocin (OT) (1). In this review we update the status of peptides and non‐peptides as (a) research tools and more

Market studies Pfizer

• China Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: 2012 is a very important year for the country as the government look to carry on their achievements following the healthcare reform in 2009. We highlight that the expansion of the National Essential Drug List (NEDL) slated to happen this year will bring strong opportunities for pharmaceuti more

• Puerto Rico Pharmaceuticals and Healthcare Report Q2 2012

  BMI View: Puerto Rico is struggling to retain its reputation as a pharmaceutical manufacturing hub, with a number of plants found to be in breach of regulations and standards over recent years. Additionally, the flagging economy is expected to push skilled staff to emigrate, leaving fewer candidates more

• Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019

  Introduction GlobalData, the industry analysis specialist, has released its new report, “Osteopenia Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Osteopenia Therapeutics market. The report identifies the more

Websites Pfizer